Novonesis A/s Class B · OMXCOP:NSIS_B

Novonesis A/s Class B — Novozymes — Q1 2014 Earnings Presentation

8 slides from Novonesis A/s Class B's earnings presentation, Apr 24, 2014

  1. Slide 1: Conference Call Q1 2014

    CONFERENCE CALL Q1 2014 April 24, 2014

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation and its related comments contain forward- looking statements, including financial expectations. Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to differ materially from expectations. Th

  3. Slide 3: Q1 2014 Summary

    Q1 2014 Summary Strong first quarter performance Sales and organic growth • 11% organic sales growth (DKK=7%). Strong as Q1 2012- Q1 2014 DKKm expected, driven by Household Care, Bioenergy and 12% 3.500 solid performance across markets 10% 11% • 30% EBIT growth driven by one-time effect from 8% The

  4. Slide 4: Sales & Markets

    Sales & Markets  Q1 2014 sales: Sales by industry, DKKm DKK +7%, LCY +10%, organic +11% Q1 2014 Q1 2013 • Household Care: Sales continued on growth track, as customer interest in optimizing formulations for Household 1.080 +7%/+10% performance, low temperature wash, and chemical Care 1.013 replacem

  5. Slide 5: Business Development Activity Update

    Business Development Activity Update The BioAg Alliance Biomass Conversion industry Biopharma technology initiated under establishment gets stamp of approval • The BioAg Alliance approved 5 new commercial scale biomass • GlaxoSmithkline’s GLP-1 and initiated February 10 conversion plants to come pro

  6. Slide 6: R&D Activity Update

    R&D Activity Update BioChemicals: R&D gears up for The BioAg Alliance Termination of Bio- polypropylene project • BioAg R&D focus on building new organization. First line of • Termination of R&D project management in place with Braskem on the development of bio-based • New R&D site to be established

  7. Slide 7: Q1 2014 Financial Performance

    Q1 2014 Financial Performance Strong results for Q1 2014 2014 2014 Realized Outlook Outlook • Double digit organic sales growth Key financials Q1 2014 April 24 Jan. 21 • The BioAg Alliance gave one-time boost to profit and Sales growth, DKK +7% 4-6% 4-7% cash flow • Better than expected underlying e

  8. Slide 8: Novozymes: Rethink Tomorrow

    novozymes’ Rethink Tomorrow

Novozymes — Q1 2014 Earnings Presentation on 6ix